Glatiramer acetate

Last updated
Glatiramer acetate
Glatiramer acetate.svg
Clinical data
Trade names Copaxone, [1] Glatopa, [2] Brabio
AHFS/Drugs.com Monograph
MedlinePlus a603016
License data
Pregnancy
category
  • AU:B1
Routes of
administration 		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
  • none
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.248.824 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C25H45N5O13
Molar mass 623.657 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Glatiramer acetate (also known as Copolymer 1, Cop-1), sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. [1] [2] Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection. [1] [2]

Contents

It is a mixture of random-sized peptides that are composed of the four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine. Myelin basic protein is the antigen in the myelin sheaths of the neurons that stimulates an autoimmune reaction in people with MS, so the peptide may work as a decoy for the attacking immune cells.

It is on the World Health Organization's List of Essential Medicines. [5]

History

Glatiramer acetate was originally discovered at the Weizmann Institute of Science. Three main clinical trials followed to demonstrate safety and efficacy: The first trial was performed in a single center, double-blind, placebo controlled trial and included 50 patients. [6] The second trial was a two-year, multi-center, randomized, double-blind, placebo controlled trial and involved 251 patients. [7] The third trial was a double-blind MRI study involving participation of 239 patients. [8]

Medical uses

Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. [1]

A 2010 Cochrane review concluded that glatiramer acetate had partial efficacy in "relapse-related clinical outcomes" but no effect on progression of the disease. [9] As a result, it is approved by the FDA for reducing the frequency of relapses, but not for reducing the progression of disability. [1] [2]

A 15-year followup of the original trial compared patients who continued with glatiramer to patients who dropped out of the trial. Patients with glatiramer had reduced relapse rates, and decreased disability progression and transition to secondary progressive MS, compared to patients who did not continue glatiramer. However, the two groups were not necessarily comparable, as it was no longer a randomized trial. There were no long-term safety issues. [10]

Adverse effects

An injection site reaction on the upper left arm Copaxone Injection Site Reaction.JPG
An injection site reaction on the upper left arm

Side effects may include a lump at the injection site (injection site reaction) in approximately 30% of users, and aches, fever, chills (flu-like symptoms) in approximately 10% of users. [11] Side effect symptoms are generally mild in nature. A reaction that involves flushing, shortness of breath, anxiety and rapid heartbeat has been reported soon after injection in up to 5% of patients (usually after inadvertently injecting directly into a vein). These side effects subside within thirty minutes. Over time, a visible dent at a repeat-injection site can occur due to the local destruction of fat tissue, known as lipoatrophy, that may develop.

More serious side effects have been reported for glatiramer acetate, according to the FDA's prescribing label, these include serious side effects to the cardiovascular, digestive (including the liver), hematopoietic, lymphatic, musculoskeletal, nervous, respiratory, and urogenital systems as well as special senses (in particular the eyes). Metabolic and nutritional disorders have also been reported; however a link between glatiramer acetate and these adverse effects has not been established. [1] [2]

It may also cause Jessner lymphocytic infiltrate. [12]

Mechanism of action

Glatiramer acetate is a random polymer (average molecular mass 6.4  kD) composed of four amino acids found in myelin basic protein. The mechanism of action for glatiramer acetate is not fully elucidated. It is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. Administration of glatiramer acetate shifts the population of T cells from proinflammatory Th1 T-cells to regulatory Th2 T-cells that suppress the inflammatory response. [13] This is done by the inhibition of secretion of proinflammatory cytokines (IL-1, IL-12, TNF, INFγ) by Th1 T-cells, thereby inducing Th2 T-cells to cross the blood–brain barrier and produce anti-inflammatory cytokines (IL-4, IL-5, IL-13, IL-10, TGF-β). [14] Given its resemblance to myelin basic protein, glatiramer acetate may act as a decoy, diverting an autoimmune response against myelin. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis (EAE), a condition induced in several animal species through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific regulatory T cells (Tregs) are induced and activated in the periphery, inhibiting the inflammatory reaction to myelin basic protein. [1] [2]

The integrity of the blood–brain barrier, however, is not appreciably affected by glatiramer acetate, at least not in the early stages of treatment. Glatiramer acetate has been shown in clinical trials to reduce the number and severity of multiple sclerosis exacerbations. [15]

Society and culture

Marketing

Glatiramer acetate has been approved for marketing in numerous countries worldwide, including the United States, Israel, Canada and 24 European Union countries. [16] [17] Approval in the U.S. was obtained in 1997. [18] Glatiramer acetate was approved for marketing in the U.K. in August 2000, and launched in December. [19] This first approval in a major European market led to approval across the European Union under the mutual recognition procedure. Iran is proceeding with domestic manufacture of glatiramer acetate. [20] [21]

Patent status

Novartis subsidiary Sandoz has marketed Glatopa since 2015, a generic version of the original Teva 20 mg formulation that requires daily injection. [22]

Teva developed a long-acting 40 mg formulation, marketed since 2015, which reduced required injections to three per week. [23] In October 2017, the FDA approved a generic version, which is manufactured in India by Natco Pharma, and imported and sold by Dutch firm Mylan. [24] [25] In February 2018, Sandoz received FDA approval for their generic version. [26] In parallel with the development and approval processes, the generic competitors have disputed Teva's newer patents, any of which if upheld, would prevent marketing of long-acting generics. [27]

While the patent on the chemical drug expired in 2015, [28] Teva obtained new US patents covering pharmaceutical formulations for long-acting delivery. [29] Litigation from industry competitors in 2016-2017 resulted in the new patents being judged invalid. [30] [31] In October 2018, the U.S. Court of Appeals for the Federal Circuit upheld the patent invalidation for obviousness. [32] [33] The case reflects the larger controversy over evergreening of generic drugs.

Related Research Articles

<span class="mw-page-title-main">Multiple sclerosis</span> Disease that damages the myelin sheaths around nerves

Multiplesclerosis (MS) is a degenerative disease in which the insulating covers called myelin sheaths, of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, visual loss, muscle weakness, and trouble with sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances.

<span class="mw-page-title-main">Interferon beta-1a</span> Cytokine in the interferon family

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

<span class="mw-page-title-main">Fingolimod</span> Chemical compound

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. It has been reported to reduce the rate of relapses in relapsing-remitting multiple sclerosis by approximately one-half over a two-year period.

<span class="mw-page-title-main">Natalizumab</span> Medication used to treat multiple sclerosis and Crohns disease

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.

<span class="mw-page-title-main">Cladribine</span> Pharmaceutical drug

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

<span class="mw-page-title-main">Sorafenib</span> Chemical compound

Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

<span class="mw-page-title-main">Ruth Arnon</span> Israeli biochemist

Ruth Arnon is an Israeli biochemist and codeveloper of the multiple sclerosis drug Copaxone. She is currently the Paul Ehrlich Professor of Immunology at the Weizmann Institute of Science, where she is researching anti-cancer and influenza vaccinations.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

<span class="mw-page-title-main">Laquinimod</span> Chemical compound

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS).

<span class="mw-page-title-main">Dirucotide</span> Chemical compound

Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids is

<span class="mw-page-title-main">Dimethyl fumarate</span> Chemical compound

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid and is named after the earth smoke plant. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis. Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis. In 2017, an oral formulation of dimethyl fumarate was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression.

<span class="mw-page-title-main">Hydrocodone/ibuprofen</span> Combination drug

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.

<span class="mw-page-title-main">Ponesimod</span> Medication for the treatment of multiple sclerosis

Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis. It is a sphingosine-1-phosphate receptor modulator.

<span class="mw-page-title-main">Ozanimod</span> Medication

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

<span class="mw-page-title-main">Siponimod</span> Chemical compound

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

Rhonda Renee Voskuhl is an American physician, research scientist, and professor. She is a member of the Brain Research Institute (BRI) at the David Geffen School of Medicine at UCLA and is the director of its Multiple Sclerosis Program. Voskuhl has published numerous scientific articles in academic journals and has served in the role of principal investigator for several treatment trials investigating potential treatments for multiple sclerosis (MS).

References

  1. 1 2 3 4 5 6 7 8 "Copaxone- glatiramer acetate injection, solution". DailyMed. 23 July 2020. Retrieved 11 November 2020.
  2. 1 2 3 4 5 6 7 "Glatopa- glatiramer acetate injection, solution". DailyMed. 31 July 2020. Retrieved 11 November 2020.
  3. ↑ "Brabio 20 mg/mL Solution for Injection, Pre-filled Syringe - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 November 2020.
  4. ↑ "Copaxone 20 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 29 September 2020. Retrieved 11 November 2020.
  5. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  6. ↑ Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V (August 1987). "A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis". The New England Journal of Medicine. 317 (7): 408–14. doi:10.1056/NEJM198708133170703. PMID   3302705.
  7. ↑ Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (July 1995). "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group". Neurology. 45 (7): 1268–76. doi:10.1212/WNL.45.7.1268. PMID   7617181. S2CID   28895177.
  8. ↑ Comi G, Filippi M, Wolinsky JS (March 2001). "European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group". Annals of Neurology. 49 (3): 290–7. doi:10.1002/ana.64. PMID   11261502. S2CID   35614752.
  9. ↑ La Mantia L, Munari LM, Lovati R (May 2010). "Glatiramer acetate for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5): CD004678. doi:10.1002/14651858.CD004678.pub2. PMID   20464733.
  10. ↑ Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. (March 2010). "Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate". Multiple Sclerosis. 16 (3): 342–50. doi: 10.1177/1352458509358088 . PMC   2850588 . PMID   20106943.
  11. ↑ "Copaxone". MediGuard.
  12. ↑ Krafchik BR (2011). "Reaction Patterns". In Schachner LA, Hansen RC (eds.). Pediatric Dermatology. Elsevier Health Sciences. p. 1022. ISBN   978-0-7234-3665-2.
  13. ↑ Arnon R, Sela M (1999). "The chemistry of the Copaxone drug" (PDF). Chem. Israel. 1: 12–17. Archived from the original (PDF) on 2003-09-07.
  14. ↑ https://go.drugbank.com/drugs/DB05259; Glatiramer Mechanism of Action
  15. ↑ "Copaxone". All About Multiple Sclerosis.
  16. ↑ McKeage K (May 2015). "Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review". CNS Drugs. 29 (5): 425–32. doi:10.1007/s40263-015-0245-z. PMID   25906331. S2CID   30186027.
  17. ↑ Comi G, Amato MP, Bertolotto A, Centonze D, De Stefano N, Farina C, et al. (2016). "The heritage of glatiramer acetate and its use in multiple sclerosis". Multiple Sclerosis and Demyelinating Disorders. 1 (1). doi: 10.1186/s40893-016-0010-2 .
  18. ↑ "Copaxone". CenterWatch.
  19. ↑ "Teva's Copaxone approved in UK". The Pharma Letter.
  20. ↑ "Glatiramer Acetate". Tofigh Daru Research and Engineering Company. Archived from the original on 2018-10-21. Retrieved 2017-02-01.
  21. ↑ Isayev S, Jafarov T (1 May 2012). "Iran to manufacture multiple sclerosis cure". Trend News Agency.
  22. ↑ "Sandoz announces US launch of Glatopa". Novartis. 2015. Archived from the original on 2018-02-03. Retrieved 2017-02-21.
  23. ↑ Silva P (9 October 2015). "New 3-Times-Per-Week Regimen For Teva's Copaxone". Multiple Sclerosis News Today.
  24. ↑ Erman M, Grover D (3 October 2017). "Mylan surges, Teva slumps after FDA okays Copaxone copy". Reuters. Retrieved 4 October 2017.
  25. ↑ "NATCO's marketing partner Mylan receives final approval of generic glatiramer acetate, for both 20 mg/mL and 40 mg/mL versions". NATCO Pharma (India). 3 October 2017. Archived from the original on 10 January 2019. Retrieved 4 October 2017.>
  26. ↑ "Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL". Novartis International AG. February 13, 2018. Retrieved May 10, 2018.
  27. ↑ "Teva's Copaxone still growing despite patent risks". BioPharmaDive.
  28. ↑ Helfand C. "Copaxone". FiercePharma.
  29. ↑ Decker S (1 September 2016). "Teva loses decision on validity of 302 copaxone patent". Bloomberg Markets.
  30. ↑ Decker S, Flanagan C, Benmeleh Y (30 January 2017). "Teva loses ruling invalidating patents on copaxone drug". Bloomberg Markets.
  31. ↑ "Teva loses patent ruling". Briefcase. The Philadelphia Inquirer. Bloomberg News. September 2, 2017. p. A12. Retrieved June 23, 2018– via Newspapers.com (Publisher Extra).
  32. ↑ "U.S. appeals court upholds ruling that canceled Teva Copaxone patents". Reuters. October 12, 2018. Retrieved October 12, 2018.
  33. ↑ "In Re: Copaxone Consolidated Cases" (PDF). United States Court of Appeals for the Federal Circuit. October 12, 2018. Retrieved October 12, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.